Theoretical and Practical Application of Traditional and Accelerated Titration Phase I Clinical Trial Designs: The Wayne State University Experience

REFERENCES

• Ahn , C. ( 1998 ). An evaluation of Phase I cancer clinical trial designs . Stat. Med. 17 ( 14 ): 1537 – 1549 .
   Google Scholar
• Alousi , A. M. , Boinpally , R. , Wiegand , R. , Parchment , R. , Gadgeel , S. , Heilbrun , L. K. , Wozniak , A. J. , DeLuca , P. , LoRusso , P. M. ( 2007 ). A Phase 1 trial of XK469: toxicity profile of a selective topoisomerase IIbeta inhibitor . Invest. New Drugs 25 ( 2 ): 147 – 154 .
   Google Scholar
• Cheung , Y. K. , Chappell , R. ( 2000 ). Sequential designs for Phase I clinical trials with late-onset toxicities . Biometrics 56 ( 4 ): 1177 – 1182 .
   PubMed Web of Science ®Google Scholar
• Collins , J. M. , Zaharko , D. S. , Dedrick , R. L. , Chabner , B. A. ( 1986 ). Potential roles for preclinical pharmacology in Phase I clinical trials . Cancer Treat. Rep. 70 ( 1 ): 73 – 80 .
   Google Scholar
• Edler , L. ( 1990 ). Statistical requirements of Phase I studies . Onkologie 13 ( 2 ): 90 – 95 .
   Google Scholar
• Gadgeel , S. M. , Boinpally , R. R. , Heilbrun , L. K. , Wozniak , A. , Jain , V. , Redman , B. , Zalupski , M. , Wiegand , R. , Parchment , R. , LoRusso , P. M. ( 2003 ). A Phase I clinical trial of spicamycin derivative KRN5500 (NSC 650426) using a Phase I accelerated titration “2B” design . Invest. New Drugs 21 ( 1 ): 63 – 74 .
   Google Scholar
• Gadgeel , S. M. , Wozniak , A. , Boinpally , R. R. , Wiegand , R. , Heilbrun , L. K. , Jain , V. , Parchment , R. , Colevas , D. , Cohen , M. B. , LoRusso , P. M. ( 2005 ). Phase I clinical trial of BMS-247550, a derivative of epothilone B, using accelerated titration 2B design . Clin. Cancer Res. 11 ( 17 ): 6233 – 6239 .
   PubMed Web of Science ®Google Scholar
• Gelmon , K. A. , Eisenhauer , E. A. , Harris , A. L. , Ratain , M. J. , Workman , P. ( 1999 ). Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development? J. Natl. Cancer Inst. 91 ( 15 ): 1281 – 1287 .
   PubMed Web of Science ®Google Scholar
• Goldsmith , M. A. , Slavik , M. , Carter , S. K. ( 1975 ). Quantitative prediction of drug toxicity in humans from toxicology in small and large animals . Cancer Res. 35 ( 5 ): 1354 – 1364 .
   Google Scholar
• Goncalves , P. H. , High , F. , Juniewicz , P. , Shackleton , G. , Li , J. , Boerner , S. , LoRusso , P. M. ( 2008 ). Phase I dose-escalation study of the thioxanthone SR271425 administered intravenously once every 3 weeks in patients with advanced malignancies . Invest. New Drugs 26 ( 4 ): 347 – 354 .
   Google Scholar
• Horstmann , E. , McCabe , M. S. , Grochow , L. , Yamamoto , S. , Rubinstein , L. , Budd , T. , Shoemaker , D. , Emanuel , E. J. , Grady , C. ( 2005 ). Risks and benefits of Phase 1 oncology trials, 1991 through 2002 . N. Engl. J. Med. 352 ( 9 ): 895 – 904 .
   PubMed Web of Science ®Google Scholar
• Jasti , B. R. L. P. , Parchment , R. E. , Wozniak , A. J. , Flaherty , L. E. , Shields , A. F. , Zalupski , M. , Zwiebel , J. (2001). Phase I clinical trial of fenretinide (NSC374551) in advanced solid tumors. Proc. Am. Soc. Clin. Oncol. 485.
   Google Scholar
• Korn , E. L. ( 2004 ). Nontoxicity endpoints in Phase I trial designs for targeted, noncytotoxic agents . J. Natl. Cancer Inst. 96 ( 13 ): 977 – 978 .
   Google Scholar
• Koyfman , S. A. , Agrawal , M. , Garrett-Mayer , E. , Krohmal , B. , Wolf , E. , Emanuel , E. J. , Gross , C. P. ( 2007 ). Risks and benefits associated with novel Phase 1 oncology trial designs . Cancer 110 ( 5 ): 1115 – 1124 .
   Google Scholar
• Lin , Y. , Shih , W. J. ( 2001 ). Statistical properties of the traditional algorithm-based designs for Phase I cancer clinical trials . Biostatistics 2 ( 2 ): 203 – 215 .
   PubMedGoogle Scholar
• LoRusso , P. , Foster , B. J. , Poplin , E. , McCormick , J. , Kraut , M. , Flaherty , L. , Heilbrun , L. K. , Valdivieso , M. , Baker , L. ( 1995 ). Phase I clinical trial of pyrazoloacridine NSC366140 (PD115934) . Clin. Cancer Res. 1 ( 12 ): 1487 – 1493 .
   Google Scholar
• LoRusso , P. M. , Foster , B. J. , Wozniak , A. , Heilbrun , L. K. , McCormick , J. I. , Ruble , P. E. , Graham , M. A. , Purvis , J. , Rake , J. , Drozd , M. , Lockwood , G. F. , Corbett , T. H. ( 2000 ). Phase I pharmacokinetic study of the novel antitumor agent SR233377 . Clin. Cancer Res. 6 ( 8 ): 3088 – 3094 .
   Google Scholar
• LoRusso , P. M. , Prakash , S. , Wozniak , A. , Flaherty , L. , Zalupski , M. , Shields , A. , Sands , H. , Parchment , R. , Jasti , B. ( 2002 ). Phase I clinical trial of 5-fluoro-pyrimidinone (5FP), an oral prodrug of 5-fluorouracil (5FU) . Invest. New Drugs 20 ( 1 ): 63 – 71 .
   Google Scholar
• Mani , S. , McDaid , H. , Hamilton , A. , Hochster , H. , Cohen , M. B. , Khabelle , D. , Griffin , T. , Lebwohl , D. E. , Liebes , L. , Muggia , F. , Horwitz , S. B. ( 2004 ). Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors . Clin. Cancer Res. 10 ( 4 ): 1289 – 1298 .
   PubMed Web of Science ®Google Scholar
• Parulekar , W. R. , Eisenhauer , E. A. ( 2004 ). Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: Theory and practice . J. Natl. Cancer Inst. 96 ( 13 ): 990 – 907 .
   PubMed Web of Science ®Google Scholar
• Penta , J. S. , Rosner , G. L. , Trump , D. L. ( 1992 ). Choice of starting dose and escalation for Phase I studies of antitumor agents . Cancer Chemother. Pharmacol. 31 ( 3 ): 247 – 250 .
   Google Scholar
• Prakash , S. , Foster , B. J. , Meyer , M. , Wozniak , A. , Heilbrun , L. K. , Flaherty , L. , Zalupski , M. , Radulovic , L. , Valdivieso , M. , LoRusso , P. M. ( 2001 ). Chronic oral administration of CI-994: A Phase 1 study . Invest. New Drugs 19 ( 1 ): 1 – 11 .
   Google Scholar
• Schneiderman , M. ( 1967 ). Mouse to man: Statistical problems in bringing a drug to clinical trial . In: Proceedings of the Fifth Berkely Symposium on Mathematical Statistics and Probability . Berkley, CA : University of California Press , pp. 885 – 866 .
   Google Scholar
• Simon , R. , Freidlin , B. , Rubinstein , L. , Arbuck , S. G. , Collins , J. , Christian , M. C. ( 1997 ). Accelerated titration designs for Phase I clinical trials in oncology . J. Natl. Cancer Inst. 89 ( 15 ): 1138 – 1147 .
   PubMed Web of Science ®Google Scholar
• Spriggs , D. S. S. , Bienvenu , B. , Letrent , S. , Lebwohl , D. , Jones , S. , Burris , H. ( 2001 ). Phase I First-in-Man study of the epothilone B analog BMS-247550 in patients with advanced cancer . Proc. Am. Soc. Clin. Oncol. 428 .
   Google Scholar
• Supko , J. G. , Eder , J. P. Jr ., Ryan , D. P. , Seiden , M. V. , Lynch , T. J. , Amrein , P. C. , Kufe , D. W. , Clark , J. W. ( 2003 ). Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors . Clin. Cancer Res. 9 ( 14 ): 5178 – 5186 .
   Google Scholar
• Wadler , S. L. E. , Pilat , M. , Malburg , L. , Holloway , S. , Matthews , N. , Shackleton , G. , Valdivieso , M. , LoRusso , P. ( 2005 ). A Phase I trial of SR271425 given as a one hour infusion every 3 weeks in patients with advanced solid tumors . Proc. Am. Soc. Clin. Oncol. 2030 .
   Google Scholar